Elevation Oncology Expands Pipeline with Nomination of EO-1022 for the Treatment of HER3-expressing Solid Tumors December 18, 2024
KeyVibe and KEYFORM Clinical Programs of Vibostolimab and Favezelimab Fixed-Dose Combinations with Pembrolizumab to be discontinued December 18, 2024
CAN-2409 Achieved Primary Endpoint in Ph 3 Prostate Cancer Trial, Showing Significantly Improved DFS December 18, 2024
Jemperli (dostarlimab-gxly) receives US FDA Breakthrough Therapy Designation for locally advanced dMMR/MSI-H rectal cancer December 18, 2024
FDA Approves UNLOXCYT™ (cosibelimab-ipdl) for advanced cutaneous squamous cell carcinoma December 18, 2024
Biocytogen Announces Adcendo ApS Exercises Antibody Option to Accelerate ADC Development December 18, 2024
Reprioritized pipeline focus on LAVA-1266 and plan to discontinue development of LAVA-1207 December 18, 2024
Efficacy threshold not achieved in Ph 1 dose escalation trial for FHD-286 + decitabine to support continued development in patients with R/R AML December 18, 2024
Positive Initial Data from LOTIS-7 Trial of ZYNLONTA® in Combination with Bispecific Antibody in Patients with R/R LBCL Announced December 18, 2024
Data Characterizing Mutated KRAS Genotype and Clinical Outcomes in Patients with Advanced NSCLC Treated with Mecbotamab Vedotin (Mec-V) presented December 18, 2024
Continued Strong Improvement in OS Data from Ph 2 OVATION 2 Study of IMNN-001 Announced December 18, 2024
Positive Initial Data from First-line RAS-mutated mCRC Ph 2 CRDF-004 trial evaluating onvansertib + SoC Announced December 18, 2024
Data shows strong OS, PFS, and durability from combination of efti + pembrolizumab in difficult-to-treat head and neck cancer patients with PD-L1 CPS <1 December 18, 2024
Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Ph 1 Gynecologic Expansion Clinical Trial Announced December 18, 2024
Positive EU CHMP Opinion for WELIREG® (belzutifan) as Treatment for Adult Patients With Certain Types of VHL Disease-Associated Tumors and for Certain Previously Treated Adult Patients With Advanced RCC December 18, 2024
NDA for Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma to be submitted Before Year-End December 18, 2024
Jemperli (dostarlimab) + chemo receives positive CHMP opinion to expand approval to all adult patients with primary advanced or recurrent endometrial cancer December 18, 2024
FDA Clearance received to Administer AIV001 in Facial Skin by Intradermal Injection for Superficial and Nodular Superficial Basal Cell Carcinoma (sBCC and nBCC) December 18, 2024
